• Vaccine Name: Adenovirus vectors expressing Marburg virus glycoprotein
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004118
• Type: Recombinant vector vaccine
• Antigen: Glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
• GP from Marburg virus Ci67 gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Ci67 GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• GP from Marburg virus Ravn gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Ravn GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• Preparation: The Ci67 GP (Genbank accession number AF005735; Protein ID AAC40460.1; a.a. 1–681), Ravn GP (Genbank accession number AF005734; Protein ID AAC40459.1; a.a. 1–681), and Musoke GP (Genbank accession number DQ217792; Protein ID ABA87127; a.a. 1–681) genes were amplified by PCR. Each MARV antigen was subcloned into the pLAd and pRAd shuttle vectors to create a series of MARV adenovirus vaccines targeted against the Ci67, Ravn, and Musoke strains of MARV. All cAdVax vector genomes were based on a modified Ad5sub360 vector backbone, which contains deletions in E1, E3 and almost all E4 ORFs with the exception of ORF6 (Wang et al., 2006).
• Virulence: Although Ad vectors have a high affinity for the liver and may potentially cause inflammation in the liver, there is not pathology indicative of inflammation or cytotoxicity as a result of vaccination in mice (Wang et al., 2006).

Mouse Response

• Host Strain: C57BL/6 mice
• Vaccination Protocol: Four groups of 28 C57BL/6 mice were immunized intra-peritoneally (i.p.) at weeks 0, 4 and 8 with 1 × 10^8 pfu of either cAdVaxM(ci), cAdVaxM(ra), cAdVaxM(mu), or HC4 control vector prepared in 100 μl PBS/10% glycerol. HC4, an unrelated adenovirus-based Hepatitis C vaccine, served as a negative control vaccine. Four mice per group were sacrificed at weeks 2, 4, 6, 8, 10, 12, and 24 (Wang et al., 2006).
• Persistence: The persistence of these three vaccine candidates in mice was not reported.
• Immune Response: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) induced efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus (Wang et al., 2006).
• Side Effects: Three 1 × 10^8 pfu doses of vaccine vector did not lead to any detectable toxicity in liver or spleen, so it appears to be safe (Wang et al., 2006).
• Challenge Protocol: No challenge experiment was conducted.